ethyl-(2-morpholin-4-yl-ethyl)-carbodiimide | 23361-53-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: ethyl-(2-morpholin-4-yl-ethyl)-carbodiimide
• 英文别名: ethyl-(2-morpholino-ethyl)-carbodiimide；Aethyl-(2-morpholino-aethyl)-carbodiimid
• CAS: 23361-53-7
• 化学式: C₉H₁₇N₃O
• 分子量: 183.253
• InChiKey: NRRTWPDCIMQNOZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  37.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1-ethyl-3-(2-morpholin-4-yl-ethyl)-thiourea 在 丙酮 、 mercury(II) oxide 作用下， 生成 ethyl-(2-morpholin-4-yl-ethyl)-carbodiimide
  参考文献：
  名称：

  The Cross-linking of Gelatin Using a Water-soluble Carbodiimide

  摘要：

  DOI：

  10.1021/ja01573a075

文献信息

• RAS INHIBITORS
  申请人：Revolution Medicines, Inc.

  公开号：US20210130326A1

  公开（公告）日：2021-05-06

  The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.

  该披露涉及大环化合物，以及能够抑制Ras蛋白质的药物组合物和蛋白质复合物，以及它们在治疗癌症中的用途。
• METHOD FOR PREPARING BIOCOMPATIBLE SMALL INTESTINAL MUCOSA HYDROGEL CAPABLE OF CONTROLLING IN-VIVO DEGRADATION PERIOD
  申请人：Kim Da Yeon

  公开号：US20140328939A1

  公开（公告）日：2014-11-06

  The present invention relates to a method for preparing a biocompatible small intestinal submucosa hydrogel with a controllable in-vivo degradation period, more particularly to a method for preparing a small intestinal submucosa hydrogel which is formed in a solution phase by forming chemical crosslinkages by solubilizing a biocompatible small intestinal submucosa powder and allows the degradation period of a gel formed during in-vivo injection by controlling the degree of crosslinking and a method for preparing a small intestine submucosa drug carrier or a small intestine submucosa support using the hydrogel.
• The Cross-linking of Gelatin Using a Water-soluble Carbodiimide
  作者：John C. Sheehan、Joseph J. Hlavka

  DOI：10.1021/ja01573a075

  日期：1957.8